| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Oncopeptides AB (Record id 259984) | 268 | GlobeNewswire | With effect from April 19, 2024, the subscription rights in Nasdaq will be
traded on the list for Equity rights. Trading will continue up until and
including April 29, 2024.
Instrument: Subscription... ► Artikel lesen | |
| 15.04. | Oncopeptides AB: Oncopeptides secures national reimbursement for Pepaxti in Spain | 212 | GlobeNewswire (Europe) | - Preparations ongoing with full launch expected to commence after summer.
Stockholm, April 15, 2024 - Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, today announces... ► Artikel lesen | |
| 08.04. | Oncopeptides AB: Oncopeptides announces final terms for the fully guaranteed rights issue | 175 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR... ► Artikel lesen | |
| 04.04. | Oncopeptides AB: Oncopeptides releases first quarter 2024 sales | 51 | GlobeNewswire (Europe) | Stockholm - April 4, 2024 - Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the unaudited net sales for the first quarter of 2024.
Oncopeptides... ► Artikel lesen | |
| 27.03. | Oncopeptides AB: Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa | 417 | GlobeNewswire (Europe) | Stockholm, Sweden and Dubai, UAE, March 27, 2024 - Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO ("Vector") today announced a collaboration... ► Artikel lesen | |
| 27.02. | Oncopeptides AB: Oncopeptides publishes year-end report 2023 | 29 | GlobeNewswire (Europe) | Stockholm - February 27, 2024 - Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2023.
"Having delivered on our promise of continuous... ► Artikel lesen | |
| 23.02. | Oncopeptides' Pepaxto reaches end of the line in US after FDA yanks approval | 23 | FiercePharma |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 5.061 |
| BAYER | 3.866 |
| TUI | 3.687 |
| NEL | 3.540 |
| PLUG POWER | 3.509 |
| GAMESTOP | 3.326 |
| RHEINMETALL | 2.489 |
| AMC ENTERTAINMENT | 2.219 |
| SIEMENS ENERGY | 1.910 |
| ALIBABA | 1.686 |
| MERCEDES-BENZ | 1.677 |
| NVIDIA | 1.647 |
| NOVAVAX | 1.560 |
| NORDEX | 1.529 |
| BYD | 1.393 |
| DEUTSCHE BANK | 1.270 |
| DELIVERY HERO | 1.230 |
| AIXTRON SE | 1.197 |
| VOLKSWAGEN | 1.165 |
| RWE | 1.104 |
| TESLA | 1.082 |
| PALANTIR TECHNOLOGIES | 1.069 |
| ALLIANZ | 1.060 |
| COMMERZBANK | 1.021 |
| K+S | 939 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
